Achilles Therapeutics plc (ACHL) Misses Q3 EPS by 7c

Achilles Therapeutics plc (NASDAQ: ACHL) reported Q3 EPS of ($0.48), $0.07 worse than the analyst estimate of ($0.41).

For earnings history and earnings-related data on Achilles Therapeutics plc (ACHL) click here.

You May Also Be Interested In

• SYNNEX Corp. (SNX) Tops Q3 EPS by $1.04, Beats on Revenue; Offers Q4 Guidance
• Brightline Interactive raises $1.25M in PIPE led by drone executive
• Kala Bio and Virotek sign non-binding LOI to expand genetic testing